CAS: 533-45-9; Clomethiazole

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号137-00-8 4-甲基-5-噻唑乙醇 | CAS号853261-35-5 5-(2-乙氧基乙基)-4-甲基噻唑 | CAS号663179-27-9 2-Pentanone,3-c... | CAS号13045-13-1 3-氯-4-氧-1-戊醇 | CAS号58371-98-5 3,5-二氯-2-戊酮 | CAS号1759-28-0 4-甲基-5-乙烯基噻唑 | CAS号58981-35-4 2-(4-甲基噻唑-5-基)乙胺

合成工艺路线路线简述

    3,5-二氯-2-戊酮置于盐酸,乙醇,双氧水体系中,化学反应生成 氯美噻唑
    参考文献:De678153
    标题:De678153

    海关参考信息

    专利信息


    专利号:US-2012177593-A1
    优先权日:2009-07-20
    标 题 :Synthesis of dendrimer conjugates
    发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
    权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

    专利号:US-2008214827-A1
    优先权日:2004-02-03
    标 题:Synthesis of Cyanoimino-Benzoimidazoles
    发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
    权利人:EURO CELTIQUE SA
    摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

    专利号:US-2012282255-A1
    优先权日:2011-04-07
    标题 :Methods and compositions for the treatment of alcoholism and alcohol dependence
    发明人:PLUCINSKI GREG
    权利人:PLUCINSKI GREG
    摘要:The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated. Accordingly, the methods and compositions of the invention are useful for preventing, treating, diagnosing, or monitoring the progression various alcohol and drug dependency diseases disclosed herein.

    专利号:US-2015352230-A1
    优先权日:2013-01-11
    标 题:Synthesis and isolation of dendrimer based imaging systems
    发明人:MULLEN DOUGLAS GURNETT; BAKER JR JAMES R; BANASZAK HOLL MARK M; HUANG BAOHUA; DOUGHERTY CASEY; BALL JACK
    权利人:UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis and isolation of antibodies conjugated with modular dendrimer nanoparticles. In particular, the present invention is directed to antibodies conjugated with novel modular dendrimer nanoparticles having precise numbers of imaging agents, methods of synthesizing the same, compositions comprising such antibodies conjugated with such modular dendrimer nanoparticles, as well as systems and methods utilizing the conjugates (e.g., in imaging settings) (e.g., in diagnostic and/or therapeutic settings) (e.g., for the delivery of therapeutics, imaging, and/or targeting agents).

    专利号:US-2012232225-A1
    优先权日:2009-08-26
    标 题:Synthesis and isolation of dendrimer systems
    发明人:BAKER JR JAMES R; BANASZAK HOLL MARK M; MULLEN DOUGLAS GURNETT; ORR BRADFORD G; DESAI ANKUR; SANDER LEONARD M; WADDELL JACK NEEL
    权利人:BAKER JR JAMES R; BANASZAK HOLL MARK M; MULLEN DOUGLAS GURNETT; ORR BRADFORD G; DESAI ANKUR; SANDER LEONARD M; WADDELL JACK NEEL; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis and isolation of dendrimer systems. In particular, the present invention is directed to novel dendrimer conjugates with defined and limited numbers of ligand conjugates and high levels of structural uniformity, methods of synthesizing the same, compositions comprising the conjugates, as well systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)).

    专利号:US-9402911-B2
    优先权日:2011-12-08
    标题:Multifunctional small molecules
    发明人:BAKER JR JAMES R; HUANG BAOHUA M; THOMAS THOMMEY P
    权利人:UNIV MICHIGAN REGENTS
    摘要:The present invention relates to dendrimer synthesis. Specifically, the present invention relates to dendrimer compositions (e.g., scaffolds) capable of copper-free click conjugation for use in the synthesis of functionalized dendrimers, and methods of use of the same.
    白银承泽化工科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.chengzechem.com
    电话: 0086 943-8535351 13389336721👤
    📞白银承泽化工科技有限公司 ⚠️参考联系方式

    销售电话:0086 943-8535351 13389336721
    邮箱:sales@chengzechem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Karsy M, Brock A, Guan J, Taussky P, Kalani MY, Park MS. Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. Neurosurg Focus. 2017 Apr;42(4):E3. doi: 10.3171/2017.1.FOCUS16522. Review. Review. Review. doi: 10.1007/978-3-319-09614-8_4. Review. doi: 10.1002/14651858.CD009622.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Oct 04;10 :CD009622. Review. German. doi: 10.5507/bp.2013.089. Epub 2013 Dec 11. Review. doi: 10.1007/s40261-013-0158-x. Review. doi: 10.1111/epi.12281. Review. Alcohol, nicotine, and iatrogenic withdrawals in the ICU. Crit Care Med. 2013 Sep;41(9 Suppl 1):S57-68. doi: 10.1097/CCM.0b013e3182a16919. Review. doi: 10.1002/14651858.CD009622.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(8):CD009622. doi: 10.1007/978-94-007-5881-0_3. Review. doi: 10.1097/FTD.0b013e31822fbf7c. Review. doi: 10.1093/alcalc/agr073. Epub 2011 Jun 29. Review. doi: 10.1055/s-0030-1248443. Epub 2010 Aug 27. Review. German. Review. doi: 10.1002/14651858.CD006266.pub2. Review. doi: 10.1024/0040-5930.66.6.449. Review. German. doi: 10.1055/s-0028-1109214. Epub 2009 Apr 3. Review. German. Review.

    合成参考文献


    摘要:Shimada, K., Science of Synthesis Knowledge Updates, (2010) 1, 448.
    摘要:Acta Pharmaceutica Suecica., 7(423), 1970 []
    参考文献:10.1136/bmj.280.6212.484-c
    摘要:Low L, Stephenson JB, Goel KM. Prolonged intravenous use of chlormethiazole (Heminevrin). Br Med J. 1980 Feb 16;280(6212):484.4–484. doi: 10.1136/bmj.280.6212.484-c.
    摘要:Ghandi B, Freye E, Avril G. [Chlormetiazole in anaesthesia (author's transl)]. Anesth Analg (Paris). 1980;37(3-4):127–31.
    参考文献:10.15288/jsa.1996.57.471
    摘要:Heinz A, Schmidt K, Baum SS, Kuhn S, Dufeu P, Schmidt LG, Rommelspacher H. Influence of dopaminergic transmission on severity of withdrawal syndrome in alcoholism. J Stud Alcohol. 1996 Sep;57(5):471–4. doi: 10.15288/jsa.1996.57.471.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知